Vol 19, No 2 (2016)
Research paper
Published online: 2016-07-29

open access

Page views 2239
Article views/downloads 4039
Get Citation

Connect on Social Media

Connect on Social Media

Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC

Vera Artiko, Aida Afgan, Jelena Petrović, Branislava Radović, Nebojša Petrović, Marina Vlajković, Dragana Šobić-Šaranović, Vladimir Obradović
Pubmed: 27479786
Nucl. Med. Rev 2016;19(2):99-103.


BACKGROUND: This paper is the short review of our preliminary results obtained with 99mTc-EDDA/HYNIC-TOC.

MATERIAL AND METHODS: The total of 495 patients with different neuroendocrine tumors were investigated during last few years.

RESULTS: There have been 334 true positive (TP), 73 true negative (TN), 6 false positive (FP) and 82 false negative findings (FN). Diagnosis was made according to SPECT findings in 122 patients (25%). The mean T/NT ratio for TP cases was significantly higher (p < 0.01) on SPECT (3.12 ± 1.13) than on whole body scan (2.2 ± 0.75). According to our results, overall sensitivity of the method is 80%, specificity 92%, positive predictive value 98%, negative predictive value 47% and accuracy 82%. Fifteen TP patients underwent therapy with 90Y-DOTATATE.

CONCLUSION: Scintigraphy of neuroendocrine tumors with 99mTc-Tektrotyd is a useful method for diagnosis, staging and follow up of the patients suspected to have neuroendocrine tumors. SPECT had important role in diagnosis. It is also helpful in the appropriate choice of the therapy, including the peptide receptor radionuclide therapy. In the absence of 68Ga-labeled peptides and PET/CT, the special emphasize should be given to application of SPECT/CT as well as to the radioguided surgery.